Intersect ENT market cap is $530.8 m, and annual revenue was $109.14 m in FY 2019

Intersect ENT Gross profit (Q2, 2020)2.4 M

Intersect ENT Gross profit margin (Q2, 2020), %24.8%

Intersect ENT Net income (Q2, 2020)-23.1 M

Intersect ENT EBIT (Q2, 2020)-21.1 M

Intersect ENT Cash, 30-Jun-202029.5 M

Intersect ENT EV574.8 M

Intersect ENT revenue was $109.14 m in FY, 2019

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Revenue | 38.6m | 61.6m | 78.7m | 96.3m | 108.5m | 109.1m |

| 60% | 28% | ||||

## Cost of goods sold | 10.2m | 12.3m | 13.0m | 15.5m | 22.6m | 21.8m |

## Gross profit | 28.4m | 49.3m | 65.7m | 80.8m | 85.9m | 87.4m |

| 74% | 80% | 83% | 84% | 79% | 80% |

## R&D expense | 10.3m | 16.6m | 18.9m | 18.4m | 19.3m | 24.3m |

## General and administrative expense | 36.1m | 59.6m | 72.9m | 80.0m | 91.6m | 108.5m |

## Operating expense total | 46.4m | 76.2m | 91.8m | 98.4m | 110.9m | 132.8m |

## EBIT | (18.1m) | (26.9m) | (26.1m) | (17.6m) | (25.0m) | (45.4m) |

| (47%) | (44%) | (33%) | (18%) | (23%) | (42%) |

## Interest expense | 889.0k | 1.2m | 2.1m | 2.4m | ||

## Interest income | 125.0k | |||||

## Income tax expense | ||||||

## Net Income | (18.4m) | (26.6m) | (25.2m) | (16.4m) | (22.9m) | (43.0m) |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Cash | 13.4m | 34.8m | 9.9m | 19.8m | 9.5m | 20.7m |

## Accounts Receivable | 8.3m | 11.5m | 14.4m | 16.6m | 19.6m | 19.1m |

## Prepaid Expenses | 2.9m | 2.7m | 2.3m | |||

## Inventories | 951.0k | 1.5m | 1.3m | 8.5m | 11.6m | 17.0m |

## Current Assets | 60.3m | 141.2m | 125.3m | 130.3m | 134.7m | 129.1m |

## PP&E | 1.5m | 3.2m | 4.1m | 4.8m | 5.9m | 6.3m |

## Total Assets | 63.0m | 144.6m | 129.8m | 135.6m | 141.0m | 147.9m |

## Accounts Payable | 2.1m | 1.9m | 3.3m | 3.4m | 6.2m | 4.1m |

## Current Liabilities | 8.1m | 13.1m | 14.4m | 17.7m | 19.7m | 18.9m |

## Long-term debt | 10.9m | |||||

## Total Debt | 10.9m | |||||

## Total Liabilities | 15.4m | 18.4m | 20.0m | 29.8m | ||

## Common Stock | 30.0k | 31.0k | 32.0k | |||

## Additional Paid-in Capital | 150.4m | 253.5m | 262.9m | 282.1m | 308.8m | 348.7m |

## Retained Earnings | (96.6m) | (123.3m) | (148.5m) | (164.8m) | (187.8m) | (230.8m) |

## Total Equity | 53.8m | 130.2m | 114.4m | 117.2m | 121.0m | 118.1m |

## Financial Leverage | 1.2 x | 1.1 x | 1.1 x | 1.2 x | 1.2 x | 1.3 x |

- Source: SEC Filings

- Source: SEC Filings

USD | FY, 2014 | FY, 2015 | FY, 2016 | FY, 2017 | FY, 2018 | FY, 2019 |
---|---|---|---|---|---|---|

## Net Income | (18.4m) | (26.6m) | (25.2m) | (16.4m) | (22.9m) | (43.0m) |

## Depreciation and Amortization | 1.2m | 1.5m | 1.9m | 2.7m | ||

## Accounts Receivable | (4.1m) | (3.1m) | (3.0m) | (2.2m) | (3.0m) | 503.0k |

## Inventories | (541.0k) | (544.0k) | (1.7m) | (2.9m) | (2.5m) | (5.1m) |

## Accounts Payable | 645.0k | (230.0k) | 1.2m | 203.0k | 2.1m | (1.2m) |

## Cash From Operating Activities | 1.1m | 21.4m | (20.1m) | (8.0m) | (13.8m) | (27.3m) |

## Purchases of PP&E | (367.0k) | (1.5m) | (2.1m) | (2.3m) | (2.1m) | (3.7m) |

## Cash From Investing Activities | (35.5m) | (56.7m) | (6.9m) | 9.2m | (10.0m) | 18.9m |

## Cash From Financing Activities | 54.6m | 98.2m | 2.0m | 8.8m | 13.5m | 19.5m |

## Net Change in Cash | 10.0m | (10.4m) | 11.2m | |||

## Interest Paid | 53.0k |

- Source: SEC Filings

- Source: SEC Filings

USD | Q2, 2014 |
---|---|

## Financial Leverage | -0.2 x |

Intersect ENT's Patients was reported to be 150 k in FY, 2016.

FY, 2016 | |
---|---|

## Accounts | 2.40 k |

## Facilities | 1 |

## Patents (US) | 30 |

## Patents Issued | 77 |

## Patents Pending | 37 |

## Patients | 150 k |

## Products | 2 |

## Trademarks | 29 |

## Trademarks (US) | 4 |

## Trademarks Pending | 35 |

- Source: SEC Filings